Guo, Xiaohui
Yu, Yang
Zhang, Yongbo
Sun, Li
Li, Yufeng
Song, Bing
Hang, Li
Baba, Masayuki
Wasaki, Yosuke
Kikumori, Kunika
Murayama, Emiko
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled 14-Week Study of Mirogabalin in Chinese Patients with Diabetic Peripheral Neuropathic Pain
https://doi.org/10.1007/s40122-024-00617-2
Funding for this research was provided by:
Daiichi Sankyo Co., Ltd.
Article History
Received: 26 December 2023
Accepted: 17 May 2024
First Online: 19 June 2024
Declarations
:
: Xiaohui Guo, Yang Yu, Yongbo Zhang, Li Sun, Yufeng Li, and Bing Song received investigator fees from Daiichi Sankyo Co., Ltd. Masayuki Baba received lecture and consultancy fees from Daiichi Sankyo Co., Ltd. Yosuke Wasaki, Kunika Kikumori, and Emiko Murayama are employees of the study sponsor, Daiichi Sankyo Co., Ltd., and Li Hang is an employee of Daiichi Sankyo (China) Holdings Co., Ltd.
: The protocol for this research project has been approved by a suitably constituted Ethics Committee of the participating institutions and it conforms to the provisions of the Declaration of Helsinki. All patients provided written informed consent prior to participation. This study was registered in ClinicalTrials.gov on September 19, 2019, under the identifier NCT04094662.